144. Lennox-Gastaut syndrome Disease details / Clinical trials / Drug dev / DR info


Clinical trials : 111 Drugs : 72 - (DrugBank : 14) / Drug target genes : 49 - Drug target pathways : 61

Drugs and their primary sponsors and trial info
12-Lead ECG   
   Gillette Children's Specialty Healthcare
      2017   Phase 1/Phase 2   NCT02815540   United States;
Any other approved Antiepileptic Drug   
   Eisai Inc.
      2011   Phase 3   NCT01405053   Canada;France;Greece;India;Italy;Poland;South Africa;United States;
CBD - Oral Solution, is known as Epidiolex, and is the approved name in the USA.   
   GW Research Ltd
      2015   Phase 3   EUCTR2014-001834-27-PL   Australia;France;Israel;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-001834-27-NL   Australia;France;Israel;Netherlands;Poland;Spain;United Kingdom;United States;
Cannabidiol   
   GW Research Ltd
      2021   Phase 4   NCT05044819   United States;
   Gillette Children's Specialty Healthcare
      2017   Phase 1/Phase 2   NCT02815540   United States;
   Yonsei University
      2020   Phase 3   NCT04611438   Korea, Republic of;
   Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
      2018   Phase 1/Phase 2   NCT03467113   United States;
Cannabidiol (CBD)   
   GW Research Ltd
      2015   Phase 3   EUCTR2014-002940-42-GB   France;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002940-42-ES   France;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-001834-27-PL   Australia;France;Israel;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-001834-27-NL   Australia;France;Israel;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-001834-27-GB   Australia;France;Israel;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-001834-27-FR   France;Israel;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-001834-27-ES   France;Israel;Netherlands;Poland;Spain;United Kingdom;United States;
   GW Research Ltd.
      2015   Phase 3   EUCTR2014-002941-23-PL   Netherlands;Poland;United States;
      2015   -   EUCTR2014-002941-23-NL   Netherlands;Poland;United States;
Cannabidiol Oral Solution   
   INSYS Therapeutics Inc
      2017   Phase 3   NCT02318537   -
Carisbamate   
   SK Life Science, Inc.
      2019   Phase 1   NCT04062981   United States;
      2019   Phase 1   NCT03731715   United States;
Clobazam   
   Lundbeck LLC
      2005   Phase 3   NCT01160770   -
Clobazam High Dose   
   Lundbeck LLC
      2007   Phase 3   NCT00518713   Australia;Belarus;India;Lithuania;Serbia;United States;
      2005   Phase 2   NCT00162981   United States;
Clobazam Low Dose   
   Lundbeck LLC
      2007   Phase 3   NCT00518713   Australia;Belarus;India;Lithuania;Serbia;United States;
      2005   Phase 2   NCT00162981   United States;
Clobazam Medium Dose   
   Lundbeck LLC
      2007   Phase 3   NCT00518713   Australia;Belarus;India;Lithuania;Serbia;United States;
Clobazam PhEur   
   Lundbeck Inc
      2008   -   EUCTR2007-004322-24-LT   Bulgaria;Lithuania;
   Ovation Pharmaceuticals Inc.
      2008   -   EUCTR2007-004322-24-BG   Bulgaria;Lithuania;
Clobazam Tablets   
   Lundbeck Inc
      2008   -   EUCTR2007-004350-82-LT   Bulgaria;Lithuania;
      2008   -   EUCTR2007-004322-24-LT   Bulgaria;Lithuania;
   Ovation Pharmaceuticals
      2008   -   EUCTR2007-004350-82-BG   Bulgaria;Lithuania;
   Ovation Pharmaceuticals Inc.
      2008   -   EUCTR2007-004322-24-BG   Bulgaria;Lithuania;
E2007   
   Eisai Co., Ltd.
      2016   Phase 3   JPRN-JapicCTI-173536   Japan, Asia except Japan, North America, Europe, Oceania;
   Eisai Limited
      2018   Phase 3   EUCTR2014-002321-35-BE   Australia;Belgium;Canada;Czech Republic;France;Hungary;Italy;Japan;Korea, Republic of;Latvia;Poland;United States;
      2017   Phase 3   EUCTR2014-002321-35-LV   Australia;Belgium;Canada;Czech Republic;France;Hungary;Italy;Japan;Korea, Republic of;Latvia;Poland;United States;
      2017   Phase 3   EUCTR2014-002321-35-HU   Australia;Belgium;Canada;Czech Republic;France;Hungary;Italy;Japan;Korea, Republic of;Latvia;Poland;United States;
      2017   Phase 3   EUCTR2014-002321-35-CZ   Australia;Belgium;Canada;Czech Republic;Czechia;France;Hungary;Italy;Japan;Korea, Republic of;Latvia;Poland;United States;
      -   Phase 3   EUCTR2014-002321-35-PL   Australia;Belgium;Canada;Czech Republic;France;Hungary;Italy;Japan;Korea, Republic of;Latvia;Poland;United States;
      -   Phase 3   EUCTR2014-002321-35-FR   Australia;Belgium;Canada;Czech Republic;France;Hungary;Italy;Japan;Korea, Republic of;Latvia;Poland;United States;
E2080   
   Eisai Co, Ltd.
      -   Phase 3   EUCTR2016-004953-34-Outside-EU/EEA   Japan;
      -   Phase 3   EUCTR2016-004952-30-Outside-EU/EEA   Japan;
EZOGABINE (US ONLY)   
   GlaxoSmithKline R&D Limited
      -   -   EUCTR2012-001132-60-Outside-EU/EEA   United States;
      -   -   EUCTR2010-020154-33-Outside-EU/EEA   United States;
EZOGABINE (US only)   
   GlaxoSmithKline R&D Limited
      -   -   EUCTR2010-020154-33-Outside-EU/EEA   United States;
Ezogabine/retigabine   
   GlaxoSmithKline
      2012   Phase 2   NCT01494584   United States;
FENFLURAMINE HYDROCHLORIDE   
   Zogenix International Inc.
      2018   Phase 3   EUCTR2017-002628-26-IT   Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Japan;Mexico;Netherlands;Norway;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
   Zogenix International Limited
      2019   Phase 3   EUCTR2019-001331-31-IT   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002628-26-ES   Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Japan;Mexico;Netherlands;Norway;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
   Zogenix International Limited, a wholly owned subsidiary of Zogenix Inc.
      2019   Phase 3   EUCTR2017-002628-26-SE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Mexico;Netherlands;Norway;Poland;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002628-26-NL   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Mexico;Netherlands;Norway;Poland;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002628-26-FR   Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Japan;Mexico;Netherlands;Norway;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002628-26-DK   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Israel;Italy;Japan;Mexico;Netherlands;Norway;Poland;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002628-26-DE   Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002628-26-BE   Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Japan;Mexico;Netherlands;Norway;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2017-002628-26-PL   Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Japan;Mexico;Netherlands;Norway;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2017-002628-26-GB   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Israel;Italy;Japan;Mexico;Netherlands;Norway;Poland;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2017-002628-26-AT   Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Japan;Mexico;Netherlands;Norway;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
Fenfluramina cloridrato   
   Zogenix International Limited
      2019   Phase 3   EUCTR2019-001331-31-IT   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
Fenfluramine   
   KU Leuven
      2016   Phase 2   NCT02655198   Belgium;
   YAMAMOTO Hideichiro
      2019   Phase 3   JPRN-jRCT2041200096   Australia;Belgium;Canda;Denmark;France;Germany;Italy;Japan;Mexico;Netherland;Poland;Spain;Sweeden;US;
Fenfluramine HCl, DL-Fenfluramine, (±)-Fenfluramine   
   Zogenix International Inc.
      2018   Phase 3   EUCTR2017-002628-26-IT   Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Japan;Mexico;Netherlands;Norway;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
   Zogenix International Limited
      2018   Phase 3   EUCTR2017-002628-26-ES   Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Japan;Mexico;Netherlands;Norway;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
   Zogenix International Limited, a wholly owned subsidiary of Zogenix Inc.
      2019   Phase 3   EUCTR2017-002628-26-SE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Mexico;Netherlands;Norway;Poland;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002628-26-NL   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Mexico;Netherlands;Norway;Poland;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002628-26-FR   Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Japan;Mexico;Netherlands;Norway;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002628-26-DK   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Israel;Italy;Japan;Mexico;Netherlands;Norway;Poland;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002628-26-DE   Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002628-26-BE   Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Japan;Mexico;Netherlands;Norway;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2017-002628-26-PL   Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Japan;Mexico;Netherlands;Norway;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2017-002628-26-GB   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Israel;Italy;Japan;Mexico;Netherlands;Norway;Poland;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2017-002628-26-AT   Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Japan;Mexico;Netherlands;Norway;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
Fenfluramine hydrochloride (colorless)   
   Zogenix International Limited
      2020   Phase 3   EUCTR2019-001331-31-SE   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001331-31-NL   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001331-31-DK   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001331-31-DE   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-001331-31-GB   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-001331-31-FR   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-001331-31-ES   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2019-001331-31-PL   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2019-001331-31-BE   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
Fycompa   
   EISAI LIMITED
      2017   Phase 3   EUCTR2014-002321-35-IT   Australia;Belgium;Canada;Czech Republic;Czechia;France;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Latvia;Lithuania;Poland;United States;
   Eisai Limited
      2018   Phase 3   EUCTR2014-002321-35-BE   Australia;Belgium;Canada;Czech Republic;France;Hungary;Italy;Japan;Korea, Republic of;Latvia;Poland;United States;
      2017   Phase 3   EUCTR2014-002321-35-LV   Australia;Belgium;Canada;Czech Republic;France;Hungary;Italy;Japan;Korea, Republic of;Latvia;Poland;United States;
      2017   Phase 3   EUCTR2014-002321-35-HU   Australia;Belgium;Canada;Czech Republic;France;Hungary;Italy;Japan;Korea, Republic of;Latvia;Poland;United States;
      2017   Phase 3   EUCTR2014-002321-35-CZ   Australia;Belgium;Canada;Czech Republic;Czechia;France;Hungary;Italy;Japan;Korea, Republic of;Latvia;Poland;United States;
      -   Phase 3   EUCTR2014-002321-35-PL   Australia;Belgium;Canada;Czech Republic;France;Hungary;Italy;Japan;Korea, Republic of;Latvia;Poland;United States;
      -   Phase 3   EUCTR2014-002321-35-FR   Australia;Belgium;Canada;Czech Republic;France;Hungary;Italy;Japan;Korea, Republic of;Latvia;Poland;United States;
GW582892   
   GlaxoSmithKline R&D Limited
      -   -   EUCTR2012-001132-60-Outside-EU/EEA   United States;
      -   -   EUCTR2010-020154-33-Outside-EU/EEA   United States;
GWP42003-P   
   GW Research Ltd
      2020   Phase 4   NCT04133480   United States;
      2015   Phase 3   NCT02224573   -
      2015   Phase 3   NCT02224560   France;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002940-42-GB   France;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002940-42-ES   France;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-001834-27-PL   Australia;France;Israel;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-001834-27-NL   Australia;France;Israel;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-001834-27-GB   Australia;France;Israel;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-001834-27-FR   France;Israel;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-001834-27-ES   France;Israel;Netherlands;Poland;Spain;United Kingdom;United States;
   GW Research Ltd.
      2015   Phase 3   EUCTR2014-002941-23-PL   Netherlands;Poland;United States;
      2015   -   EUCTR2014-002941-23-NL   Netherlands;Poland;United States;
GWP42003-P 20 mg/kg/day Dose   
   GW Research Ltd
      2015   Phase 3   NCT02224690   Netherlands;Poland;United States;
Inovelon   
   EISAI LTD UK
      2011   -   EUCTR2010-023505-36-IT   Greece;Italy;
   Eisai Co, Ltd.
      -   Phase 3   EUCTR2016-004953-34-Outside-EU/EEA   Japan;
      -   Phase 3   EUCTR2016-004952-30-Outside-EU/EEA   Japan;
   Eisai Co., Ltd.
      2013   -   JPRN-JapicCTI-132169   Japan;
Investigators Choice of Approved AED   
   Eisai Ltd
      2012   -   EUCTR2010-023505-36-GR   Greece;Italy;South Africa;United States;
      -   Phase 3   EUCTR2010-023505-36-Outside-EU/EEA   Canada;United States;
      -   Phase 3   EUCTR2010-023505-36-FR   France;Greece;India;Italy;United States;
Investigators choice of approved AEDs   
   Eisai Ltd
      2012   -   EUCTR2010-023505-36-GR   Greece;Italy;South Africa;United States;
      -   Phase 3   EUCTR2010-023505-36-Outside-EU/EEA   Canada;United States;
      -   Phase 3   EUCTR2010-023505-36-FR   France;Greece;India;Italy;United States;
Lamictal   
   EISAI LTD UK
      2011   -   EUCTR2010-023505-36-IT   Greece;Italy;
Lamotrigine   
   EISAI LTD UK
      2011   -   EUCTR2010-023505-36-IT   Greece;Italy;
Melatonin   
   Institution de Lavigny
      2011   Phase 4   NCT01370486   Switzerland;
PEG   
   Nonomura Hidenori
      2021   Phase 3   JPRN-jRCT2051210073   Australia;Belgium;Canada;China,;France;Greece;Hungary;Italy;Japan;Korea;Latvia;Netherlands;Poland,;Russia;Serbia;Spain;Ukraine;United Kingdom;United States;
Perampanel   
   Eisai Co., Ltd.
      2016   Phase 3   JPRN-JapicCTI-173536   Japan, Asia except Japan, North America, Europe, Oceania;
   Eisai Inc.
      2016   Phase 3   NCT02834793   Australia;Austria;Belgium;Czechia;India;Japan;Korea, Republic of;United States;
      2015   -   NCT02307578   Belgium;Chile;Estonia;Hungary;Latvia;Lithuania;Poland;Spain;
Placebo   
   Eisai Co., Ltd.
      2016   Phase 3   JPRN-JapicCTI-173536   Japan, Asia except Japan, North America, Europe, Oceania;
Potiga   
   GlaxoSmithKline R&D Limited
      -   -   EUCTR2012-001132-60-Outside-EU/EEA   United States;
      -   -   EUCTR2010-020154-33-Outside-EU/EEA   United States;
RETIGABINE/EZOGABINE   
   GlaxoSmithKline R&D Limited
      -   -   EUCTR2010-020154-33-Outside-EU/EEA   United States;
Retigabine/Ezogabine   
   GlaxoSmithKline R&D Limited
      -   -   EUCTR2012-001132-60-Outside-EU/EEA   United States;
Retigabine/ezogabine   
   GlaxoSmithKline
      2012   Phase 3   NCT01668654   United States;
Rufinamide   
   Eisai Co., Ltd.
      2013   -   NCT02175173   Japan;
      2013   -   JPRN-JapicCTI-132169   Japan;
      2010   Phase 3   NCT01151540   Japan;
   Eisai Inc.
      2019   -   NCT03778424   Poland;
      2011   Phase 3   NCT01405053   Canada;France;Greece;India;Italy;Poland;South Africa;United States;
Rufinamide (E2080)   
   Eisai Limited
      2010   Phase 3   NCT01146951   Japan;
Rufinamide oral suspension   
   EISAI LTD UK
      2011   -   EUCTR2010-023505-36-IT   Greece;Italy;
   Eisai Ltd
      2012   -   EUCTR2010-023505-36-GR   Greece;Italy;South Africa;United States;
      -   Phase 3   EUCTR2010-023505-36-Outside-EU/EEA   Canada;United States;
      -   Phase 3   EUCTR2010-023505-36-FR   France;Greece;India;Italy;United States;
Sodio valproato   
   EISAI LTD UK
      2011   -   EUCTR2010-023505-36-IT   Greece;Italy;
Soticlestat   
   Ovid Therapeutics, Inc.
      2019   Phase 2   EUCTR2018-002485-39-PL   Australia;Canada;China;Israel;Poland;Portugal;Spain;United States;
   TAKEDA DEVELOPMENT CENTER AMERICAS INC.
      2021   Phase 3   EUCTR2021-002481-40-IT   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
   Takeda
      2022   Phase 3   NCT05163314   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United States;
      2021   Phase 3   NCT04938427   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United States;
      2018   Phase 2   NCT03635073   Australia;Canada;China;Israel;Poland;Portugal;Spain;United States;
   Takeda Development Center Americas, Inc.
      2021   Phase 3   EUCTR2021-002481-40-PL   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-002481-40-NL   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-002481-40-HU   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-002481-40-GR   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-002481-40-ES   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-002481-40-BE   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2021-002481-40-LV   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2021-002481-40-FR   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
TAK-935   
   Ovid Therapeutics, Inc.
      2019   Phase 2   EUCTR2018-002485-39-PL   Australia;Canada;China;Israel;Poland;Portugal;Spain;United States;
   TAKEDA DEVELOPMENT CENTER AMERICAS INC.
      2021   Phase 3   EUCTR2021-002481-40-IT   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
   Takeda
      2018   Phase 2   NCT03650452   Australia;Canada;China;Israel;Poland;Portugal;Spain;United States;
   Takeda Development Center Americas, Inc
      2022   Phase 3   EUCTR2021-002482-17-GR   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United States;
      -   Phase 3   EUCTR2021-002482-17-BE   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United States;
   Takeda Development Center Americas, Inc.
      2021   Phase 3   EUCTR2021-002481-40-PL   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-002481-40-NL   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-002481-40-HU   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-002481-40-GR   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-002481-40-ES   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-002481-40-BE   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2021-002481-40-Outside-EU/EEA   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2021-002481-40-LV   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2021-002481-40-FR   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
Topimarate   
   EISAI LTD UK
      2011   -   EUCTR2010-023505-36-IT   Greece;Italy;
Topimarato   
   EISAI LTD UK
      2011   -   EUCTR2010-023505-36-IT   Greece;Italy;
Topiramate   
   Janssen Cilag Pharmaceutica S.A.C.I., Greece
      2003   -   NCT00297349   -
   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
      1993   Phase 3   NCT00236756   -
   National Center for Research Resources (NCRR)
      1993   Phase 3   NCT00004776   -
Turmeric   
   NYU Langone Health
      2018   -   NCT03254680   United States;
ZX008   
   Zogenix International Limited
      2020   Phase 3   EUCTR2019-001331-31-SE   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001331-31-NL   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001331-31-DK   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001331-31-DE   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-001331-31-IT   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-001331-31-GB   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-001331-31-FR   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-001331-31-ES   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2019-001331-31-PL   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2019-001331-31-BE   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
ZX008 (Fenfluramine Hydrochloride)   
   Zogenix, Inc.
      2019   Phase 3   NCT03936777   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
ZX008 0.2 or 0.8 mg/kg/day   
   Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
      2017   Phase 3   NCT03355209   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United States;
ZX008 0.2 to 0.8 mg/kg/day   
   Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
      2018   Phase 1/Phase 2   NCT03467113   United States;